drugset / Trial / NCT02254304
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
Phase 4
Completed
106 enrolled
Merck KGaA, Darmstadt, Germany
Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or relapsing multiple sclerosis (RMS).
Timeline
- Start
- 2014-12-31
- Primary completion
- 2016-08-20
- Completion
- 2016-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon beta-1a | Protein / enzyme biologic | 44 ug | Subcutaneous |